Pharmaceutical Research Journal Joins Web of Science Core Collection with Strong First Impact Factor

The Journal of Pharmaceutical Investigation, a peer-reviewed publication covering pharmaceutical research and development, has been abstracted and indexed in the Science Citation Index Expanded, widely known as SciSearch, since 2021. According to the journal’s published indexing record, the 2022 journal impact factor stands at 5.5, a figure that places the title in the first quartile of its category, ranked 48th out of 278 journals in Pharmacology and Pharmacy. For a journal whose name signals its focus on pharmaceutical investigation rather than bulk volume publishing, the combination of inclusion in one of the most established citation databases and a top-quartile ranking within two years of entering the index represents a notable milestone in the competitive landscape of scholarly publishing in the pharmaceutical sciences.

Abstracting and indexing is the process by which a bibliographic database systematically catalogs a journal’s articles, capturing standardized metadata such as titles, authors, affiliations, abstracts, keywords and references, and making that metadata searchable across a global platform. The practical consequence for researchers is discoverability. An article that appears only on an individual journal website exists in a kind of bibliographic isolation, reachable mainly by readers who already know the journal. Once a journal is indexed in the Science Citation Index Expanded, its content becomes discoverable through Web of Science search tools, its citation links become traceable through the database’s cited-reference searching, and its cumulative performance becomes visible to the librarians, funders and evaluation committees who rely on these databases when they assess journals and institutions. In an era when most literature discovery begins with a database query rather than a browse of a journal’s table of contents, indexing status is a structural determinant of a paper’s audience.

The Science Citation Index Expanded is the multidisciplinary extension of the original Science Citation Index, the citation database created by Eugene Garfield in the 1960s and now maintained as part of the Web of Science Core Collection. The index covers thousands of journals across the natural sciences, applied sciences and medicine, and its selection process is deliberately selective. Editors evaluating a journal for inclusion consider a range of quality signals: the rigor and consistency of peer review, the international diversity of the editorial board and authorship, the regularity of publication, the ethical publishing standards in place, and the citation behavior of the journal’s published content. Journals are re-evaluated continuously, and inclusion is not permanent, which means that a journal’s presence in the index is itself an ongoing signal that its editorial standards continue to meet the database’s criteria.

The impact factor reported alongside the indexing record is the metric most closely watched by authors deciding where to submit their work. Calculated annually by Clarivate from the citation data in the Web of Science, the two-year impact factor for a given year is the ratio of citations received in that year to the number of substantive items, typically articles and reviews, published in the journal during the two preceding years. A 2022 impact factor of 5.5 therefore reflects citations accumulated in 2022 by papers published in 2020 and 2021, divided by the count of those papers. For a journal that entered the index in 2021, this figure arrives early in its indexed life, since new journals typically need a settling period before their citation patterns stabilize. The value of 5.5 indicates that, on average, each citable item published in the journal during the measurement window drew more than five citations in the following year, a level of citation intensity that corresponds to a strong, internationally visible research venue in the pharmaceutical field.

Quartile placement translates that raw number into context. Journals in a Web of Science category are ranked by impact factor and divided into four groups, with the first quartile, Q1, containing the top 25 percent. The Journal of Pharmaceutical Investigation’s position at 48 out of 278 journals in Pharmacology and Pharmacy places it firmly within that top band, ahead of roughly four-fifths of the journals in its category. The rank matters because impact factors are meaningful only in comparison. A value of 5.5 might be modest in a field with extremely high citation rates and exceptional in a field where citation density is low; the quartile ranking situates the journal relative to the actual distribution of its peers in pharmacology and pharmacy. Authors evaluating potential outlets, and readers skimming reference lists for authoritative sources, use these rankings as a fast heuristic for gauging where a journal stands within its discipline.

The downstream effects of this status are practical for the research community. Authors gain a publication venue whose indexed metrics can be cited in grant applications, promotion dossiers and funder reports, where journal quality is often assessed through Web of Science-based indicators. Institutions benefit because their researchers’ publications contribute to institutional citation profiles and to the global university rankings that draw heavily on Web of Science data. Readers benefit from the cited-reference network that the index builds, allowing them to trace the lineage of a finding backward through earlier work and forward through later citations. Librarians use the indexing record and the impact factor when making subscription decisions, which in turn supports the journal’s financial sustainability. In this way, a single indexing milestone ripples outward through nearly every stakeholder in the scientific communication system.

The pharmaceutical sciences present a particularly demanding environment for journal metrics. The field spans drug discovery, formulation science, pharmacokinetics, drug delivery systems, clinical pharmacology and regulatory science, and its publication landscape is crowded with long-established titles backed by major societies and commercial publishers. Citation behavior in the field is shaped by translational urgency: work on delivery platforms, biologics and therapeutic development often draws attention from both basic researchers and clinical communities, which can drive citation counts upward for journals positioned at those intersections. A journal focused on pharmaceutical investigation sits naturally in that translational zone, and the first-quartile ranking suggests that its published research is being picked up across both the pharmaceutical technology and the pharmacology communities that make up its readership.

At the same time, the announcement is a fitting occasion to recall the limits of the metrics involved. The research community has increasingly emphasized responsible use of quantitative indicators. The San Francisco Declaration on Research Assessment, signed by thousands of journals, funders and institutions, urges that impact factors not be used as a surrogate for the quality of individual papers or the merit of individual researchers, since citation counts are influenced by article type, review articles inflate averages, and two-year windows capture only a slice of a paper’s scholarly lifetime. Altitude within a quartile shifts year to year as citation patterns fluctuate, and a journal’s impact factor is a property of the journal, not a guarantee about any single article it publishes. The appropriate reading of the 2022 record is therefore as a signal of the journal’s overall standing and editorial health, not as a per-article quality certificate.

For the broader community of pharmaceutical researchers, the development adds one more indexed, first-quartile outlet to a field where the demand for visible, credible publication venues remains intense. Inclusion in the Science Citation Index Expanded from 2021 onward means that the journal’s recent volumes are being woven into the global citation fabric that underlies literature search, systematic review, bibliometric analysis and research evaluation. Its 2022 impact factor of 5.5 and its Q1 position at 48 of 278 journals in Pharmacology and Pharmacy provide a quantified snapshot of that integration. Whether the journal sustains and improves those numbers will depend on the same fundamentals that determine any journal’s trajectory: the quality and relevance of the research it attracts, the rigor of its peer review, and its continued adherence to the editorial standards that earned it entry into one of scholarly publishing’s most closely watched databases.

Subject of Research: Indexing of the Journal of Pharmaceutical Investigation in the Science Citation Index Expanded and its 2022 impact factor of 5.5 in pharmacology and pharmacy.

Article Title: Abstracting and Indexing

Article References: Abstracting and Indexing. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: abstracting and indexing, Science Citation Index Expanded, impact factor, Journal of Pharmaceutical Investigation, pharmacology, pharmacy, Web of Science, quartile ranking, scholarly publishing, pharmaceutical sciences, journal metrics, research visibility